Exenatide vs Melanotan II
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Side-by-Side Comparison
| Aspect | Exenatide | Melanotan II |
|---|---|---|
| Mechanism | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. |
| Typical Dosage | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. |
| Administration | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. |
| Side Effects | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. |
| Best For |
What They Have in Common
Both Exenatide and Melanotan II are commonly used for: